Brief summary

An Investigator-initiated, multi-center, randomized controlled trial to compare the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high bleeding risk.

Primary endpoints

Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, MI, TVR, stroke and major bleeding events (BARC 3 or 5) at 12 months.

CERC Services

•  Kick-off activities
• Clinical trials documentation
• Project management
• Clinical Events Committee (CEC) activities
• Corelab activities 
• Data monitoring Committee (DMC) activities
• Statistical activities
• Administrative tasks

Countries 

The Netherlands

Centers number

10 centers managed by CERC.